We are live on ! Find out more
SRPT icon

Sarepta Therapeutics
SRPT

179 hedge funds and large institutions have $1.21B invested in Sarepta Therapeutics in 2017 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 44 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $108M | Put options by funds: $54.9M

45% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 44

39% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 28

11% more capital invested

Capital invested by funds: $1.08B → $1.21B (+$123M)

2.09% more ownership

Funds ownership: 72.29% → 74.38% (+2.1%)

1% more funds holding

Funds holding: 177 → 179 (+2)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
179
Holders Change
+2
Holders Change %
+1.13%
% of All Funds
4.46%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
39
Increased
64
Reduced
44
Closed
28
Calls
$108M
Puts
$54.9M
Net Calls
+$53.5M
Net Calls Change
+$36.4M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$160M
2
HM
HealthCor Management
New York
+$48M
3
CCM
Camber Capital Management
Massachusetts
+$41.8M
4
O
OrbiMed
New York
+$32.6M
5
PC
PointState Capital
New York
+$19.8M

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$62.4M
2
PA
Perceptive Advisors
New York
-$30.9M
3
ACA
Avoro Capital Advisors
New York
-$27.7M
4
JG
Jefferies Group
New York
-$26M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
WMSA
76
Weiss Multi-Strategy Advisers
New York
$1.33M +$1.39M +45,000 New
PCM
77
Prelude Capital Management
New York
$1.26M +$1.2M +38,752 +1,041%
Squarepoint
78
Squarepoint
New York
$1.24M -$154K -4,965 -11%
IGIM
79
I.G. Investment Management
Manitoba, Canada
$1.18M – – –
Manulife (Manufacturers Life Insurance)
80
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.15M +$145K +4,676 +14%
Russell Investments Group
81
Russell Investments Group
United Kingdom
$1.13M +$462K +14,919 +64%
American Century Companies
82
American Century Companies
Missouri
$1.11M -$7.27K -235 -0.6%
MLICM
83
Metropolitan Life Insurance Company (MetLife)
New York
$1.05M – – –
ProShare Advisors
84
ProShare Advisors
Maryland
$1.04M -$281K -9,093 -21%
VEA
85
Virtus ETF Advisers
New York
$1.02M +$103K +3,321 +11%
CCI
86
Columbus Circle Investors
$1.01M +$670K +21,652 +175%
Macquarie Group
87
Macquarie Group
Australia
$977K – – –
CM
88
Crestline Management
Texas
$965K +$1.01M +32,600 New
BBHC
89
Brown Brothers Harriman & Co
New York
$929K – – –
AIG
90
American International Group
New York
$899K +$179K +5,796 +24%
LOAMU
91
Lombard Odier Asset Management (USA)
New York
$888K +$928K +30,000 New
LCM
92
Landscape Capital Management
New Jersey
$882K – – –
NFA
93
Nationwide Fund Advisors
Ohio
$875K -$329K -10,625 -26%
SAM
94
Sectoral Asset Management
Quebec, Canada
$852K – – –
N
95
Nuveen
North Carolina
$846K +$311K +10,048 +54%
State Board of Administration of Florida Retirement System
96
State Board of Administration of Florida Retirement System
Florida
$798K – – –
CCMH
97
Cornerstone Capital Management Holdings
New York
$760K +$619K +20,003 +351%
UCFA
98
United Capital Financial Advisors
Texas
$754K – – –
DekaBank Deutsche Girozentrale
99
DekaBank Deutsche Girozentrale
Germany
$718K -$61.9K -2,000 -7%
SCA
100
Secor Capital Advisors
New York
$713K +$745K +24,082 New
2 3
4
5 6

SRPT Hedge Fund Activity: Q1 2017 in Review

179 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2017, worth a combined $1.21B — up 11% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new SRPT positions and 28 closed out — a net gain of 11 holders — while 64 added to existing stakes and 44 trimmed.

The largest buyer was BlackRock, adding an estimated $160M. The largest seller was Sabby Management, exiting entirely with an estimated $62.4M sold.

  • 179 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2017, up from 177 in Q4 2016.
  • Funds reported $1.21B of Sarepta Therapeutics stock for Q1 2017, up 11% quarter-over-quarter.
  • 39 funds opened new Sarepta Therapeutics positions in Q1 2017 and 28 closed out, a net change of +11 holders.
  • The largest Sarepta Therapeutics buyer in Q1 2017 was BlackRock, an estimated $160M added.
  • The largest Sarepta Therapeutics seller in Q1 2017 was Sabby Management, an estimated $62.4M sold.

Based on aggregated 13F filings for Q1 2017.